A Randomized, Double-Blind, Placebo-Controlled, Study of the Safety and Efficacy of Farletuzumab in Combination With a Platinum Containing Doublet in Chemotherapy-Naїve Subjects With Stage IV Adenocarcinoma of the Lung

Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the lung classified as
stage IV

- Confirmed folate receptor-alpha (FRA) expression by IHC

- Measurable disease with at least one unidimensionally measurable lesion according to
RECIST criteria version 1.1 by CT or MRI scans (CT or MRI scans must have been
performed within 30 days prior to the first dose of farletuzumab or placebo)

- Must have received no prior chemotherapy, radiation therapy or surgery with curative
intent for adenocarcinoma of the lung

Exclusion Criteria:

- Subjects who have had previous chemotherapy for adenocarcinoma of the lung

- Prior surgery with curative intent for adenocarcinoma of the lung

- Prior radiotherapy for adenocarcinoma of the lung. (Prior treatment with local
radiotherapy for symptom control [i.e., palliative radiation with non-curative
intent] is permitted)